161 related articles for article (PubMed ID: 16550573)
1. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
4. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of clinical characteristics of extraovarian peritoneal serous papillary carcinoma with papillary serous ovarian carcinoma].
Peng YZ; Shen K; Wu M; Huang HF; Pan LY; Yang JX; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):243-5. PubMed ID: 15924670
[TBL] [Abstract][Full Text] [Related]
6. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Ben-Baruch G; Sivan E; Moran O; Rizel S; Menczer J; Seidman DS
Gynecol Oncol; 1996 Mar; 60(3):393-6. PubMed ID: 8774644
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
8. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
9. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
10. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
11. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma.
Killackey MA; Davis AR
Gynecol Oncol; 1993 Nov; 51(2):171-4. PubMed ID: 8276289
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
13. [Survival in patients with clear cell carcinoma of the ovary].
Nakano T; Enoki K; Nakashima M; Ishikawa H; Ametani Y; Ohta S; Ohkuchi A; Satake S; Kojima Y; Funamoto H; Tateno M; Miwa A
Gan To Kagaku Ryoho; 1998 Jan; 25(1):67-73. PubMed ID: 9464331
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
16. Allelotype of papillary serous peritoneal carcinomas.
Cass I; Baldwin RL; Fasylova E; Fields AL; Klinger HP; Runowicz CD; Karlan BY
Gynecol Oncol; 2001 Jul; 82(1):69-76. PubMed ID: 11426964
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
18. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
Bloss JD; Liao SY; Buller RE; Manetta A; Berman ML; McMeekin S; Bloss LP; DiSaia PJ
Gynecol Oncol; 1993 Sep; 50(3):347-51. PubMed ID: 8406199
[TBL] [Abstract][Full Text] [Related]
19. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
20. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
